Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
03/2009
03/19/2009US20090076161 Deuterium-enriched bupropion
03/19/2009US20090076159 Deuterium-enriched eplivanserin
03/19/2009US20090076156 Use of a noradrenergic agonist, e.g. guanfacine, for the treatment of cognitive disorders
03/19/2009US20090076147 Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
03/19/2009US20090076145 Deuterium-enriched amibegron
03/19/2009US20090076142 Use of the irritating principal oleocanthal in olive oil, as well as structurally and functionally similar compounds
03/19/2009US20090076130 Compounds for the inhibition of histone deacetylase
03/19/2009US20090076122 PARP Modulators and Treatment of Cancer
03/19/2009US20090076121 Deuterium-enriched sumatriptan
03/19/2009US20090076106 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels
03/19/2009US20090076101 Thiophene and Thiazole Substituted Trifluoroethanone Derivatives as Histone Deacetylase (HDAC) Inhibitors
03/19/2009US20090076098 Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
03/19/2009US20090076085 Deuterium-enriched nicraven
03/19/2009US20090076083 Deuterium-enriched saredutant
03/19/2009US20090076081 Piperidine derivatives as nk3 antagonists
03/19/2009US20090076079 Deuterium-enriched methylphenidate
03/19/2009US20090076078 New compounds 966
03/19/2009US20090076066 Deuterium-enriched zolpidem
03/19/2009US20090076062 Organic Compounds
03/19/2009US20090076059 Deuterium-enriched dianicline
03/19/2009US20090076053 Methods and compositions for treating pain
03/19/2009US20090076052 Deuterium-enriched nalmefene
03/19/2009US20090076048 Deuterium-enriched xaliproden
03/19/2009US20090076037 Bicyclic pyrimidine kinase inhibitors
03/19/2009US20090076036 Deuterium-enriched risperidone
03/19/2009US20090076035 Deuterium-enriched paliperidone
03/19/2009US20090076030 Piperazine compounds
03/19/2009US20090076027 Deuterium-enriched lurasidone
03/19/2009US20090076023 Local Anesthetic Methods and Kits
03/19/2009US20090076020 Cyclopropyl Amide Derivatives 978
03/19/2009US20090076019 Methods for treating neurological disorders or damage
03/19/2009US20090076010 Deuterium-enriched lamotrigine
03/19/2009US20090076003 Phthalazine Derivatives with Angiogenesis Inhibiting Activity
03/19/2009US20090075994 Deuterium-enriched radafaxine
03/19/2009US20090075988 phosphodiesterase inhibitors such as 1-[3-(4-fluoro-phenyl-piperazin-1-yl]-6,7-dimethoxy-isoquinoline-4-carbonitrile, having improved solubility, metabolic stability and/or bioavailability, used for the treatment of neurodegenerative diseases, psychological disorders and drug addiction
03/19/2009US20090075985 Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease
03/19/2009US20090075984 Materials and methods relating to protein aggregation in neurodegenerative disease
03/19/2009US20090075983 Novel Diazabicycloalkane Derivatives and Their Medical Use
03/19/2009US20090075982 Piperazine compounds
03/19/2009US20090075981 INHIBITORS OF p38
03/19/2009US20090075978 Substituted propiolic acid amides and their use for producing drugs
03/19/2009US20090075977 Deuterium-enriched mk0974
03/19/2009US20090075975 Arylsulfonamides and uses related thereto
03/19/2009US20090075948 Compositions and methods for regulating cellular protection
03/19/2009US20090075947 Deuterium-enriched fospropofol
03/19/2009US20090075912 Use of Timosaponin BII in the Preparation Of A Medicament or Product for the Prevention and Treatment of Stroke
03/19/2009US20090075901 treatment of cell damage caused by ischemia or stroke by administering to a cell or a tissue an effective amount of an isozyme specific delta PKC (protein kinase C) antagonist
03/19/2009US20090075900 Therapeutic agent for motor neuron disease
03/19/2009US20090075888 Cardiovascular and Brain Cell Therapy Using Intracellular Ryanodine Receptor Modulation by the Estrogen Receptor Beta
03/19/2009US20090075872 Methods and means
03/19/2009US20090075865 Novel medicament for ameliorating dyskinesia
03/19/2009US20090075864 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
03/19/2009US20090075373 Neural progenitor cells derived from embryonic stem cells
03/19/2009US20090074890 Substituted Triazoles as Sodium Channel Blockers
03/19/2009US20090074862 Low-dose doxepin formulations and methods of making and using the same
03/19/2009US20090074859 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
03/19/2009US20090074857 Glycerophospholipids for the improvement of cognitive functions
03/19/2009US20090074854 Combined-step process for pharmaceutical compositions
03/19/2009US20090074788 Antibody Against Periostin, and a Pharmaceutical Composition comprising it for Preventing or Treating a Disease in which Periostin is Involved
03/19/2009US20090074779 Neurotrophin-derived peptide sequences
03/19/2009US20090074775 Use Of Anti-AB Antibody To Treat Traumatic Brain Injury
03/19/2009US20090074774 Fgfr binding peptides
03/19/2009US20090074748 Immunological control of beta-amyloid levels in vivo
03/19/2009US20090074746 Compounds to treat alzheimer's disease
03/19/2009US20090074731 Method of isolation and use of cells derived from first trimester umbilical cord tissue
03/19/2009US20090074722 Products and methods for treating PTP lar diseases
03/19/2009US20090074720 Methods for decreasing immune response and treating immune conditions
03/19/2009DE112005003001B4 Aus humanem Fettgewebe abgeleitete multipotente Stammzellen und diese enthaltende Zelltherapeutika Derived from human adipose tissue stem cells and multipotent stem cell therapeutics containing them
03/19/2009CA2731204A1 Use of a peptide as a therapeutic agent
03/19/2009CA2704726A1 Use of a defensin peptide as a therapeutic agent
03/19/2009CA2704129A1 Preparation and component intended to be added to a tobacco product
03/19/2009CA2699464A1 Piperidine derivatives as nk3 receptor antagonists
03/19/2009CA2699384A1 Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists
03/19/2009CA2699383A1 Azacyclylisoquinolinone and isoindolinone derivatives as histamine-3 antagonists
03/19/2009CA2699286A1 Piperidine derivatives as agonists of muscarinic receptors
03/19/2009CA2699236A1 Cell growth method and pharmaceutical preparation for tissue repair and regeneration
03/19/2009CA2699222A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699215A1 (d-leu7 ) -histrelin as a therapeutic agent
03/19/2009CA2699167A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699152A1 Spirocyclic aminoquinolones as gsk-3 inhibitors
03/19/2009CA2699151A1 Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
03/19/2009CA2699040A1 Perharidines
03/19/2009CA2699026A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699020A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699012A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699010A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699008A1 Use of a peptide as a therapeutic agent
03/19/2009CA2699006A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698992A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698985A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698984A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698981A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698980A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698978A1 Use of human neuropeptide af as a therapeutic agent
03/19/2009CA2698977A1 Use of c-type natriuretic peptide, alone or incombination with neuropeptide af, as a therapeutic agent
03/19/2009CA2698976A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698974A1 Use of a peptide as a therapeutic agent
03/19/2009CA2698971A1 Use of urodilatin as a therapeutic agent
03/19/2009CA2698966A1 Use of fertirelin and delta-endorphin as therapeutic agents
03/19/2009CA2698963A1 Use of a peptide as a therapeutic agent
1 ... 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 ... 1833